Characteristics and conflicts of public speakers at meetings of the oncologic drugs advisory committee to the US Food and Drug Administration
Cet article rend compte de la position du comité consultatif pour les médicaments anticancéreux de la FDA pour caractériser et éviter les conflits d'intérêts, financiers et autres, des intervenants lors de présentations pour l'autorisation de mise sur le marché d'un médicament
This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers. The Oncologic Drugs Advisory Committee advises the US Food and Drug Administration (FDA) about medications for the treatment of cancer. The committee’s meeting agenda typically includes presentations by both a company seeking marketing approval for an oncologic drug that it sponsors and by the FDA, as well as a public hearing for comments by other speakers. Speakers may be patients with cancer or may represent patient advocacy organizations, and speakers are asked to disclose financial associations with the sponsoring company or other relevant financial associations.